ChEMBL ligand: CHEMBL141 (Lamivudine teva pharma b.v., Epivir, Lamivudine component of /zidovudine teva, Lamivudine component of combivir, Virolam, GR-109714X, Lamivudine component of epzicom, Lamivudina, 3TC, GR 109714X, Lamivudine component of dovato, Lamivudine teva, Lamivudine component of symfi, Lamivudine component of dutrebis, Lamivudine component of cimduo, NSC-760061, Lamivudinum, BCH 189, (-)-, Lamivudine component of temixys, Epivir-hbv, Lamivudine component of delstrigo, Zeffix, Lamivudine component of kivexa, Lamivudine component of trizivir, Lamivudine component of triumeq, GR109714X, Lamivudine)
Core antigen in Hepatitis B virus [ChEMBL: CHEMBL1075091] [UniProtKB: Q03732] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL247] [UniProtKB: Q72547] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Core antigen in Hepatitis B virus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075091] [UniProtKB: Q03732]
ChEMBL	Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level measured after 72 hrs by PCR analysis	B	4	pIC50	>100000	nM	IC50	Eur J Med Chem (2019) 176: 41-49 [PMID:31091479]
ChEMBL	Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 4 uM supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis	B	7	pIC50	<100	nM	IC50	Eur J Med Chem (2019) 176: 41-49 [PMID:31091479]
ChEMBL	Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in tetracycline-induced cccDNA formation by measuring reduction in HBe antigen secretion after 14 days by ELISA	B	5	pEC50	>10000	nM	EC50	Eur J Med Chem (2017) 138: 407-421 [PMID:28688280]
ChEMBL	Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication incubated for 3 days by strand preferential qPCR analysis	B	6.43	pEC50	370	nM	EC50	Eur J Med Chem (2021) 225: 113780-113780 [PMID:34438123]
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547]
ChEMBL	In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant	B	4.3	pEC50	>50000	nM	EC50	Bioorg Med Chem Lett (2003) 13: 1993-1996 [PMID:12781181]
ChEMBL	In vitro antiviral activity against HIV-1 Reverse transcriptase wild type	B	7.38	pEC50	42	nM	EC50	Bioorg Med Chem Lett (2003) 13: 1993-1996 [PMID:12781181]

ChEMBL data shown on this page come from version 36:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]